Global Ovarian Cancer Drugs Market Research and Analysis - 2015-2022

  • ID: 4263786
  • Report
  • Region: Global
  • Orion Market Research Private Limited
1 of 4
The Global Ovarian Cancer Drugs Market is Expected to Grow at a CAGR of 14.09% During 2017-2022

FEATURED COMPANIES

  • Abraxane
  • Alza
  • Astra Zeneca
  • Bristol-Myers Squibb
  • Clovis Oncology
  • Eli Lilly And Company
  • MORE
Market Insights
The Global Ovarian Cancer Drugs Market is expected to grow at a CAGR of 14.09% during 2017-2022. Ovarian cancer is one of the most dangerous cancers among all different cancers in females. This cancer grows inside an ovary, results in abnormal growth of cells that have the tendency to attack or harmfully affect the other parts of the body. Ovarian cancer is difficult to predict since very few vague symptoms show up in the early stages. When the cancer grows considerably it starts to show symptoms which includes abdominal puffiness, inflating, pelvic ache, and loss of appetite. This cancer can spread in the different parts of the body associated with ovary such as liver, lymph nodes, abdomen layers, lining of the bowel and bladder. This diseases is very rare in nature, however, the risk in such kind of cancer is relatively higher. Around 10% of ovarian cancer cases are related to inherited genetic risk.

Moreover, there are an estimated 50% chances of development of these diseases to women with mutations in the breast cancer genes. The most common ovarian cancer is ovarian carcinoma.The market is boosted by the increasing incidence of ovarian cancer, rising aged women population. The need for more effective treatment options is pushing growth of the global ovarian cancer drugs market. High cost of ovarian cancer drugs and inaccurate diagnostic of ovarian cancer acts as a barrier in the growth of this market. The report includes detailed Market Overview, Analyst Insights and predictive analysis, Market Determinants, Market Segmentation, Geographical Analysis, Strategic Recommendations, Key Company Analysis, Key Findings, Market Insights and Company Profiling.

Geographical Insights
Geographically market is divided into North America, Europe, Asia Pacific and Rest of the World. North America is having the largest market share in this market. U.S and Canada are the two major countries in this region. The major factors that thrives this market are increasing number of aging population, presence of major market players, and adoption of latest technologies. Asia pacific region is expected to show high growth rates in the upcoming years in the ovarian cancer drugs market globally. China and India are anticipated to be the fastest growing ovarian cancer drug markets in Asia Pacific region. Some of the key boosting forces for ovarian cancer drug market in emerging countries arelarge pool of patients, rise in healthcare expenditure, and rising government funding.

Competitive Insights
The key players in the global ovarian cancer drugs market includes Roche, BoehringerIngelheim, Amgen, Astrazeneca, Glaxosmithkline, Abraxane, Doxil, Exelixis, Delmar Pharmaceuticals Inc, Bristol-Myers Squibb, Celgene, Alkeran, Lynparza, Novartis Pharmaceuticals Corp, Clovis Oncology, Alza, Eli Lilly And Company, GlaxosmithklinePlc, Janssen Pharmaceuticals, Inc., Novogen, Inc., Genentech Inc. and so forth. Partnership, r&d, m&a, product launch are the key strategy adopted in the global corrosion inhibitor market.

Market Segmentation
GlobalOvarian Cancer Drugs Marketis segmented on the basis ofcancer type, treatment, drugs and regional outlook. In cancer type segment the major cancer type is primary peritoneal carcinoma. This is the most common ovarian cancer type.

1. Global Ovarian Cancer Drugs Market Research And Analysis, By Cancer Type
1.1. Epithelial Ovarian Tumors
1.2. Ovarian Germ Cell Tumors
1.3. Ovarian Stromal Tumors
1.4. Primary Peritoneal Carcinoma
2. Global Ovarian Cancer Drugs Market Research And Analysis, By Treatment
2.1. Chemotherapy
2.1.1. Localized Ovarian Cancer Therapeutics
2.1.2. Metastatic Ovarian Cancer Therapeutics
2.1.3. Recurrent Ovarian Cancer Therapeutics
2.2. Immunotherapy
2.3. Hormonal Therapy
2.4. Targeted Therapy
2.5. Radiation Therapy
2.6. Surgery
3. Global Ovarian Cancer Drugs Market Research And Analysis, By Drugs
3.1. Alkeran (Melphalan)
3.2. Avastin (Bevacizumab)
3.3. Bevacizumab
3.4. Carboplatin
3.5. Clafen (Cyclophosphamide)
3.6. Cisplatin
3.7. Cyclophosphamide
3.8. Cytoxan (Cyclophosphamide)
3.9. Doxorubicin Hydrochloride
3.10. Dox-Sl (Doxorubicin Hydrochloride Liposome)
3.11. Doxil (Doxorubicin Hydrochloride Liposome)
3.12. Doxorubicin Hydrochloride Liposome
3.13. Evacet (Doxorubicin Hydrochloride Liposome)
3.14. Gemcitabine Hydrochloride
4. GlobalGlobal Ovarian Cancer Drugs Market Research And Analysis, By Region
4.1. North America
4.2. Europe
4.3. APAC
4.4. RoW

Report covers:
  • Comprehensive research methodology of Global Ovarian Cancer Drugs Market
  • This report also includes detailed and extensive market overview with key analyst insights
  • Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations
  • Analysis of regional regulations and other government policies impacting the Global Ovarian Cancer Drugs Market
  • Insights about market determinants which are stimulating the Global Ovarian Cancer Drugs Market
  • Detailed and extensive market segments with regional distribution of forecasted revenues
  • Extensive profiles and recent developments of market players
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abraxane
  • Alza
  • Astra Zeneca
  • Bristol-Myers Squibb
  • Clovis Oncology
  • Eli Lilly And Company
  • MORE
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. by Segments
1.2.2. by Geography
1.2.3. by Stakeholders
2.4. Exceptions

2. Market Overview and Insights
2.1. Definition
2.2. Analyst Insights & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendation
2.2.3. Conclusion
2.3. Raw Material Analysis
2.4. Regulation
2.4.1.1. United States
2.4.1.2. European Union
2.4.1.3. China
2.4.1.4. India

3. Market Determinant
3.1. Motivators
3.1.1. High Increase in Healthcare Expenditure
3.1.2. Increasing Healthcare Awareness
3.1.3. Increasing Incidences of Ovarian Cancer Worldwide
3.1.4. Greater Use of Combination Therapies for the Treatment
3.2. Restraint
3.2.1. Lack of Accurate Diagnosis of Ovarian Cancer
3.2.2. Launch of Generic Drugs
3.3. Opportunity
3.3.1. Rising Population of Females in Asia Pacific Region
3.3.2. Technological Advancement in Drug Sector

4. Market Segmentation
4.1. Global Ovarian Cancer Drugs Market Research and Analysis, by Cancer Type
4.1.1. Epithelial Ovarian Tumours
4.1.2. Ovarian Germ Cell Tumours
4.1.3. Ovarian Stromal Tumours
4.1.4. Primary Peritoneal Carcinoma
4.2. Global Ovarian Cancer Drugs Market Research and Analysis, by Treatment
4.2.1. Chemotherapy
4.2.1.1. Localized Ovarian Cancer Therapeutics
4.2.1.2. Metastatic Ovarian Cancer Therapeutics
4.2.1.3. Recurrent Ovarian Cancer Therapeutics
4.2.2. Targeted Therapy
4.2.3. Radiation Therapy
4.2.4. Immunotherapy
4.2.5. Hormonal Therapy
4.2.6. Surgery
4.3. Global Ovarian Cancer Drugs Market Research and Analysis, by Drugs
4.4.1. Alkeran (Melphalan)
4.4.2. Avastin (Bevacizumab)
4.4.3. Bevacizumab
4.4.4. Carboplatin
4.4.5. Clafen (Cyclophosphamide)
4.4.6. Cisplatin
4.4.7. Cyclophosphamide
4.4.8. Cytoxan (Cyclophosphamide)
4.4.9. Doxorubicin Hydrochloride
4.4.10. Dox-Sl (Doxorubicin Hydrochloride Liposome)
4.4.11. Doxil (Doxorubicin Hydrochloride Liposome)
4.4.12. Doxorubicin Hydrochloride Liposome
4.4.13. Evacet (Doxorubicin Hydrochloride Liposome)
4.4.14. Gemcitabine Hydrochloride

5. Competitive Landscape
5.1. Key Strategies
5.2. Key Company Analysis

6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. Uk
6.2.2. Germany
6.2.3. Spain
6.2.4. France
6.2.5. Italy
6.2.6. Roe
6.3. Asia Pacific
6.3.1. India
6.3.2. China
6.3.3. Japan
6.3.4. Roapac
6.4. Rest of the World

7. Company Profiles
7.1. Abraxane
7.1.1. Introduction
7.1.2. Abraxane Product Portfolio
7.1.3. Abraxane Recent Activities
7.2. Alkeran
7.2.1. Introduction
7.2.2. Alkeran Product Portfolio
7.2.3. Alkeran Recent Activities
7.3. Alza
7.3.1. Introduction
7.3.2. Alza Product Portfolio
7.3.3. Alza Recent Activities
7.4. Amgen
7.4.1. Introduction
7.4.2. Amgen Product Portfolio
7.4.3. Amgen Recent Activities
7.5. Astrazeneca
7.5.1. Introduction
7.5.2. Astrazeneca Product Portfolio
7.5.3. Astrazeneca Recent Activities
7.6. Boehringer Ingelheim
7.6.1. Introduction
7.6.2. Boehringer Ingelheim Product Portfolio
7.6.3. Boehringer Ingelheim Recent Activities
7.7. Bristol-Myers Squibb
7.7.1. Introduction
7.7.2. Bristol-Myers Squibb Product Portfolio
7.7.3. Bristol-Myers Squibb Recent Activities
7.8. Celgene
7.8.1. Introduction
7.8.2. Celgene Product Portfolio
7.8.3. Celgene Recent Activities
7.9. Clovis Oncology
7.9.1. Introduction
7.9.2. Clovis Oncology Product Portfolio
7.9.3. Clovis Oncology Recent Activities
7.10. Delmar Pharmaceuticals Inc
7.10.1. Introduction
7.10.2. Delmar Pharmaceuticals Inc Product Portfolio
7.10.3. Delmar Pharmaceuticals Inc Recent Activities
7.11. Doxil
7.11.1. Introduction
7.11.2. Doxil Product Portfolio
7.11.3. Doxil Recent Activities
7.12. Eli Lilly and Company
7.12.1. Introduction
7.12.2. Eli Lilly and Company Product Portfolio
7.12.3. Eli Lilly and Company Recent Activities
7.13. Exelixis
7.13.1. Introduction
7.13.2. Exelixis Product Portfolio
7.13.3. Exelixis Recent Activities
7.14. Genentech Inc.
7.14.1. Introduction
7.14.2. Genentech Inc. Product Portfolio
7.14.3. Genentech Inc. Recent Activities
7.15. Glaxosmithkline
7.15.1. Introduction
7.15.2. Glaxosmithkline Product Portfolio
7.15.3. Glaxosmithkline Recent Activities
7.16. Janssen Pharmaceuticals, Inc.
7.16.1. Introduction
7.16.2. Janssen Pharmaceuticals, Inc. Product Portfolio
7.16.3. Janssen Pharmaceuticals, Inc. Recent Activities
7.17. Lynparza
7.17.1. Introduction
7.17.2. Lynparza Product Portfolio
7.17.3. Lynparza Recent Activities
7.18. Novartis Pharmaceuticals Corp
7.18.1. Introduction
7.18.2. Novartis Pharmaceuticals Corp Product Portfolio
7.18.3. Novartis Pharmaceuticals Corp Recent Activities
7.19. Novogen, Inc.
7.19.1. Introduction
7.19.2. Novogen, Inc. Product Portfolio
7.19.3. Novogen, Inc. Recent Activities
7.20. Roche
7.20.1. Introduction
7.20.2. Roche Product Portfolio
7.20.3. Roche Recent Activities

List of Tables
Table 1 Global Ovarian Cancer Drugs Market Research and Analysis, by Cancer Type 2015-2022 ($Million)
Table 2 Epithelial Ovarian Tumours Market Research and Analysis, 2015-2022 ($Million)
Table 3 Ovarian Germ Cell Tumours Market Research and Analysis, 2015-2022 ($Million)
Table 4 Ovarian Stromal Tumours Market Research and Analysis, 2015-2022 ($Million)
Table 5 Primary Peritoneal Carcinoma Market Research and Analysis, 2015-2022 ($Million)
Table 6 Global Ovarian Cancer Drugs Market Research and Analysis, by Treatment 2015-2022 ($Million)
Table 7 Chemotherapy Market Research and Analysis, 2015-2022 ($Million)
Table 8 Localized Ovarian Cancer Therapeutics Market Research and Analysis, 2015-2022 ($Million)
Table 9 Metastatic Ovarian Cancer Therapeutics Market Research and Analysis, 2015-2022 ($Million)
Table 10 Recurrent Ovarian Cancer Therapeutics Market Research and Analysis, 2015-2022 ($Million)
Table 11 Targeted Therapy Market Research and Analysis, 2015-2022 ($Million)
Table 12 Radiation Therapy Market Research and Analysis, 2015-2022 ($Million)
Table 13 Immunotherapy Market Research and Analysis, 2015-2022 ($Million)
Table 14 Hormonal Therapy Market Research and Analysis, 2015-2022 ($Million)
Table 15 Surgery Market Research and Analysis, 2015-2022 ($Million)
Table 16 Global Ovarian Cancer Drugs Market Research and Analysis, by Drugs 2015-2022 ($Million)
Table 17 Instruments Market Research and Analysis, 2015-2022 ($Million)
Table 18 Services and Softwares Market Research and Analysis, 2015-2022 ($Million)
Table 19 Reagents Market Research and Analysis, 2015-2022 ($Million)
Table 20 Global Ovarian Cancer Drugs Market Research and Analysis, by End Users
Table 21 Alkeran (Melphalan) Market Research and Analysis, 2015-2022 ($Million)
Table 22 Avastin (Bevacizumab) Market Research and Analysis, 2015-2022 ($Million)
Table 23 Bevacizumab Market Research and Analysis, 2015-2022 ($Million)
Table 24 Carboplatin Market Research and Analysis, 2015-2022 ($Million)
Table 25 Clafen (Cyclophosphamide) Market Research and Analysis, 2015-2022 ($Million)
Table 26 Cisplatin Market Research and Analysis, 2015-2022 ($Million)
Table 27 Cyclophosphamide Market Research and Analysis, 2015-2022 ($Million)
Table 28 Cytoxan (Cyclophosphamide) Market Research and Analysis, 2015-2022 ($Million)
Table 29 Doxorubicin Hydrochloride Market Research and Analysis, 2015-2022 ($Million)
Table 30 Dox-Sl (Doxorubicin Hydrochloride Liposome) Market Research and Analysis, 2015-2022 ($Million)
Table 31 Doxil (Doxorubicin Hydrochloride Liposome) Market Research and Analysis, 2015-2022 ($Million)
Table 32 Doxorubicin Hydrochloride Liposome Market Research and Analysis, 2015-2022 ($Million)
Table 33 Evacet (Doxorubicin Hydrochloride Liposome) Market Research and Analysis, 2015-2022 ($Million)
Table 34 Gemcitabine Hydrochloride Market Research and Analysis, 2015-2022 ($Million)
Table 35 Abraxane Product Portfolio
Table 36 Abraxane Recent Activities
Table 37 Alkeran Product Portfolio
Table 38 Alkeran Recent Activities
Table 39 Alza Product Portfolio
Table 40 Alza Recent Activities
Table 41 Amgen Product Portfolio
Table 42 Amgen Recent Activities
Table 43 Astrazeneca Product Portfolio
Table 44 Astrazeneca Recent Activities
Table 45 Boehringer Ingelheim Product Portfolio
Table 46 Boehringer Ingelheim Recent Activities
Table 47 Bristol-Myers Squibb Product Portfolio
Table 48 Bristol-Myers Squibb Recent Activities
Table 49 Celgene Product Portfolio
Table 50 Celgene Recent Activities
Table 51 Clovis Oncology Product Portfolio
Table 52 Clovis Oncology Recent Activities
Table 53 Delmar Pharmaceuticals Inc Product Portfolio
Table 54 Delmar Pharmaceuticals Inc Recent Activities
Table 55 Doxil Product Portfolio
Table 56 Doxil Recent Activities
Table 57 Eli Lilly and Company Product Portfolio
Table 58 Eli Lilly and Company Recent Activities
Table 59 Exelixis Product Portfolio
Table 60 Exelixis Recent Activities
Table 61 Genentech Inc. Product Portfolio
Table 62 Genentech Inc. Recent Activities
Table 63 Glaxosmithkline Product Portfolio
Table 64 Glaxosmithkline Recent Activities
Table 65 Janssen Pharmaceuticals, Inc. Product Portfolio
Table 66 Janssen Pharmaceuticals, Inc. Recent Activities
Table 67 Lynparza Product Portfolio
Table 68 Lynparza Recent Activities
Table 69 Novartis Pharmaceuticals Corp Product Portfolio
Table 70 Novartis Pharmaceuticals Corp Recent Activities
Table 71 Novogen, Inc. Product Portfolio
Table 72 Novogen, Inc. Recent Activities
Table 73 Roche Product Portfolio
Table 74 Roche Recent Activities

List of Figures
Figure 1 North American Market Research and Analysis, 2015-2022 ($Million)
Figure 2 United States Market Research and Analysis, 2015-2022 ($Million)
Figure 3 Canada Market Research and Analysis, 2015-2022 ($Million)
Figure 4 European Market Research and Analysis, 2015-2022 ($Million)
Figure 5 Uk Market Research and Analysis, 2015-2022 ($Million)
Figure 6 Germany Market Research and Analysis, 2015-2022 ($Million)
Figure 7 Spain Market Research and Analysis, 2015-2022 ($Million)
Figure 8 France Market Research and Analysis, 2015-2022 ($Million)
Figure 9 Italy Market Research and Analysis, 2015-2022 ($Million)
Figure 10 Roe Market Research and Analysis, 2015-2022 ($Million)
Figure 11 Asia Pacific Market Research and Analysis, 2015-2022 ($Million)
Figure 12 India Market Research and Analysis, 2015-2022 ($Million)
Figure 13 China Market Research and Analysis, 2015-2022 ($Million)
Figure 14 Japan Market Research and Analysis, 2015-2022 ($Million)
Figure 15 Ropac Market Research and Analysis, 2015-2022 ($Million)
Figure 16 Rest of the World Market Research and Analysis, 2015-2022 ($Million)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Roche
  • Boehringer Ingelheim
  • Amgen
  • Astra Zeneca
  • GlaxoSmithKline
  • Abraxane
  • Doxil
  • Exelixis
  • Delmar Pharmaceuticals Inc
  • Bristol-Myers Squibb
  • Celgene
  • Alkeran
  • Lynparza
  • Novartis Pharmaceuticals Corp
  • Clovis Oncology
  • Alza
  • Eli Lilly And Company
  • Janssen Pharmaceuticals, Inc.
  • Novogen, Inc.
  • Genentech Inc.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll